Kathryn S Nevel1, Jessica A Wilcox2, Lindsay J Robell3, Yoshie Umemura4. 1. Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 2. Department of Neurology, NewYork-Presbyterian Hospital, Weill Cornell Medical Center, 520 E 70th St, Starr Pavilion 607, New York, NY, 10021, USA. 3. Department of Neurology, University of Michigan, 1914 Taubman Center, 1500 E. Medical Center Dr., SPC 5316, Ann Arbor, MI, 48109-5316, USA. 4. Department of Neurology, University of Michigan, 1914 Taubman Center, 1500 E. Medical Center Dr., SPC 5316, Ann Arbor, MI, 48109-5316, USA. yoshie@med.umich.edu.
Abstract
PURPOSE OF REVIEW: Liquid biopsy is a sampling of tumor cells or tumor nucleotides from biofluids. This review explores the roles of liquid biopsy for evaluation and management of patients with primary and metastatic CNS malignancies. RECENT FINDINGS: Circulating tumor cell (CTC) detection has emerged as a relatively sensitive and specific tool for diagnosing leptomeningeal metastases. Circulating tumor DNA (ctDNA) detection can effectively demonstrate genetic markup of CNS tumors in the cerebrospinal fluid, though its role in managing CNS malignancies is less well-defined. The value of micro RNA (miRNA) detection in CNS malignancies is unclear at this time. Current standard clinical tools for the diagnosis and monitoring of CNS malignancies have limitations, and liquid biopsy may help address clinical practice and knowledge gaps. Liquid biopsy offers exciting potential for the diagnosis, prognosis, and treatment of CNS malignancies, but each modality needs to be studied in large prospective trials to better define their use.
PURPOSE OF REVIEW: Liquid biopsy is a sampling of tumor cells or tumor nucleotides from biofluids. This review explores the roles of liquid biopsy for evaluation and management of patients with primary and metastatic CNS malignancies. RECENT FINDINGS: Circulating tumor cell (CTC) detection has emerged as a relatively sensitive and specific tool for diagnosing leptomeningeal metastases. Circulating tumor DNA (ctDNA) detection can effectively demonstrate genetic markup of CNS tumors in the cerebrospinal fluid, though its role in managing CNS malignancies is less well-defined. The value of micro RNA (miRNA) detection in CNS malignancies is unclear at this time. Current standard clinical tools for the diagnosis and monitoring of CNS malignancies have limitations, and liquid biopsy may help address clinical practice and knowledge gaps. Liquid biopsy offers exciting potential for the diagnosis, prognosis, and treatment of CNS malignancies, but each modality needs to be studied in large prospective trials to better define their use.
Authors: Carme Balaña; Jose Luis Ramirez; Miquel Taron; Yannis Roussos; Aurelio Ariza; Rosa Ballester; Carme Sarries; Pedro Mendez; Jose Javier Sanchez; Rafael Rosell Journal: Clin Cancer Res Date: 2003-04 Impact factor: 12.531
Authors: E Racila; D Euhus; A J Weiss; C Rao; J McConnell; L W Terstappen; J W Uhr Journal: Proc Natl Acad Sci U S A Date: 1998-04-14 Impact factor: 11.205
Authors: Josie Hayes; Helene Thygesen; Charlotte Tumilson; Alastair Droop; Marjorie Boissinot; Thomas A Hughes; David Westhead; Jane E Alder; Lisa Shaw; Susan C Short; Sean E Lawler Journal: Mol Oncol Date: 2014-11-28 Impact factor: 6.603
Authors: G D Sorenson; D M Pribish; F H Valone; V A Memoli; D J Bzik; S L Yao Journal: Cancer Epidemiol Biomarkers Prev Date: 1994 Jan-Feb Impact factor: 4.254
Authors: Priya Balasubramanian; Robert J Kinders; Shivaani Kummar; Vishal Gupta; David Hasegawa; Anoop Menachery; Scott M Lawrence; Lihua Wang; Katherine Ferry-Galow; Darren Davis; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow Journal: PLoS One Date: 2017-04-12 Impact factor: 3.240
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Tugce Kutuk; G Daniel Grass; Daniel Oliver; Sepideh Mokhtari; Solmaz Sahebjam; Sungjune Kim; Jose Penagaricano; Hsiang-Hsuan Michael Yu; Nam Tran; Arnold Etame; Jennifer L Peterson; Peter Forsyth; Timothy Robinson Journal: Adv Radiat Oncol Date: 2022-03-09
Authors: David E Piccioni; Achal Singh Achrol; Lesli A Kiedrowski; Kimberly C Banks; Najee Boucher; Garni Barkhoudarian; Daniel F Kelly; Tiffany Juarez; Richard B Lanman; Victoria M Raymond; Minhdan Nguyen; Judy D Truong; Annie Heng; Jaya Gill; Marlon Saria; Sandeep C Pingle; Santosh Kesari Journal: CNS Oncol Date: 2019-03-11
Authors: Endika Prieto-Fernández; Ana María Aransay; Félix Royo; Esperanza González; Juan José Lozano; Borja Santos-Zorrozua; Nuria Macias-Camara; Monika González; Raquel Pérez Garay; Javier Benito; Africa Garcia-Orad; Juan Manuel Falcón-Pérez Journal: Theranostics Date: 2019-06-19 Impact factor: 11.556
Authors: Olga A Sindeeva; Roman A Verkhovskii; Mustafa Sarimollaoglu; Galina A Afanaseva; Alexander S Fedonnikov; Evgeny Yu Osintsev; Elena N Kurochkina; Dmitry A Gorin; Sergey M Deyev; Vladimir P Zharov; Ekaterina I Galanzha Journal: Cells Date: 2019-10-02 Impact factor: 7.666